Under the background that the core assets of A-Shares are fully exploited, fund managers are trying to find investment opportunities on the subdivision track.
According to the statistics of the reporter of the securities times, the annual report data disclosed by recently listed companies show that many leading stocks in subdivided industries are favored by fund managers. Glenn, who has just been promoted to 100 billion fund manager, has excavated two new pharmaceutical stocks, both of which are leading stocks in the pharmaceutical industry. The Hangzhou Youngsun Intelligent Equipment Co.Ltd(603901) , Shenzhen H&T Intelligent Control Co.Ltd(002402) and others concerned by Zhu Shaoxing, a veteran of public investment, are also the leaders of relevant industries.
The analysis shows that after the valuation of new energy, consumption and other topics, the investment cost performance advantage of leading companies is not significant. At this time, it is important to find more than expected subdivided fields and subdivided tracks. In fact, some unpopular segments have low capital attention, and fund managers can often obtain excess returns against the trend.
Gran pays attention to the leader of the pharmaceutical segment
Since the second half of last year, the pharmaceutical theme fund managed by Glenn has retreated greatly, but this does not affect its attention to pharmaceutical stocks.
On March 11, Suzhou Nanomicro Technology Co.Ltd(688690) , Apt Medical Inc(688617) announced the annual financial report of 2021, and China Europe medical health, which is known as the “goddess of medicine” by the market, appeared in the list of the top ten shareholders of the company. Among them, Suzhou Nanomicro Technology Co.Ltd(688690) obtained 1.3634 million new positions of Gelan, with a market value of 109 million yuan at the end of the period, ranking the second largest circulating shareholder.
Xingquan Heyi and Xingquan Herun managed by Xie Zhiyu also appeared in the list of the top ten shareholders of the company, but Xie Zhiyu reduced some Suzhou Nanomicro Technology Co.Ltd(688690) positions through the two funds Xingquan Heyi reduced 551100 shares in the fourth quarter, held 1058700 shares at the end of the period, and the market value of its position was 85 million yuan. Xingquan Herun reduced its holdings of 602200 shares, holding 785800 shares at the end of the period, with a market value of 63 million yuan.
In addition, Suzhou Nanomicro Technology Co.Ltd(688690) also attracted the attention of Wu Xingwu, manager of Guangfa fund. In the fourth quarter, 541000 new shares were held, ranking the eighth largest circulating shareholder.
Statistics show that Suzhou Nanomicro Technology Co.Ltd(688690) is a leading enterprise in the R & D and large-scale production of high-performance nano microsphere materials in China. The company has broken the long-term monopoly of foreign enterprises on the high-end chromatographic filler Market and accelerated the domestic substitution process of high-performance chromatographic products. According to the company’s annual report for 2021, the company achieved a total revenue of 446 million yuan in 2021, a year-on-year increase of 117.7%; The net profit attributable to the parent company was 188 million yuan, a year-on-year increase of 158.8%.
Cinda Securities believes that benefiting from the rising demand for antibody drug separation and purification of pharmaceutical enterprises, the company has increasingly close cooperation with many large pharmaceutical enterprises in China, the number and scale of project applications have increased significantly, and the revenue of affinity chromatography media and ion exchange chromatography media used for macromolecular drug separation and purification has increased rapidly. Boosted by the vigorous development of downstream antibody drugs, vaccines and other fields, the scale of the company is expected to achieve rapid growth.
Apt Medical Inc(688617) also won the favor of Ge Lan, the top flow fund manager of 100 billion yuan. During the fourth quarter, Ge Lan’s new China Europe medical and health management bought Apt Medical Inc(688617) 242900 shares, with a stock market value of 68 million yuan at the end of the period, ranking among the top ten circulating shareholders.
Apt Medical Inc(688617) also attracted the attention of Wu Xingwu, manager of GF fund, top flow institutions such as Citic Securities Company Limited(600030) , Gaoyi assets, etc Citic Securities Company Limited(600030) in the fourth quarter, Apt Medical Inc(688617) 356900 shares were newly purchased, and the market value of the position at the end of the period was 100 million yuan. Gao yiliwei selected Weishi fund also bought 266200 new shares, with a market value of 75 million yuan at the end of the period.
Apt Medical Inc(688617) is the leader of electrophysiological consumables in China. Driven by “catheter ablation + vascular intervention”, it is expected to achieve high-speed growth and fully enjoy the bonus of domestic substitution. In 2021, the company achieved a revenue of 829 million yuan, a year-on-year increase of 72.85%; The net profit attributable to shareholders of listed companies was 208 million yuan, a year-on-year increase of 87.7%.
Sinolink Securities Co.Ltd(600109) believes that the company participated in the bidding for volume procurement in many regions in 2021 and performed well in the selection results of coronary balloon, guide wire, guide tube and other products. Due to the large space for the company to increase its market share in China, the high growth trend of channel products is expected to continue in the future. The company is leading in the field of electrophysiology and vascular intervention. In the future, it is expected to maintain the leading position in China and gradually seize the market share of foreign-funded enterprises.
Liu Gesong’s reduction of children’s drug leading
Liu geqing won the title of equity management of Guangfa in 2019. After becoming famous, the fund managed by Liu Gesong received a large influx of funders, and its management scale also increased rapidly.
On March 11, Shandong Wit Dyne Health Co.Ltd(000915) disclosed the financial report of 2021. GF dual engine upgraded hybrid securities investment fund, GF innovation upgraded flexible allocation hybrid securities investment fund and GF diversified emerging stock securities investment fund managed by Liu Gesong appeared in the list of the top ten circulating shareholders of the company. GF dual engine upgraded hybrid securities investment fund reduced its holdings of 4 million shares Shandong Wit Dyne Health Co.Ltd(000915) positions in the fourth quarter, held 5.2467 million shares at the end of the period, with a market value of 160 million yuan, ranking the third largest circulating shareholder. GF innovation, upgrading and flexible allocation of hybrid securities investment fund held 2.8905 million shares at the end of the period, with a market value of 88 million yuan, ranking the eighth largest circulating shareholder. GF diversified emerging equity securities investment fund’s position remained unchanged, holding 2.67 million shares at the end of the period, with a market value of 81 million yuan, ranking the ninth largest circulating shareholder.
It is understood that Shandong Wit Dyne Health Co.Ltd(000915) is a leading enterprise in children’s medicine. Its main products include ikoxin (vitamin A / D capsule), national class II new drug Irene (glimepiride tablets), yiganxin (licorice zinc granules), gaidixin (compound calcium carbonate effervescent granules) and children’s health food. In 2021, driven by its subsidiary Dayin pharmaceutical, the company realized a main business income of 2.027 billion yuan, a year-on-year increase of 11.32%; The net profit attributable to the parent company was 380 million yuan, a year-on-year increase of 30.78%.
As a pillar subsidiary, dyne pharmaceutical’s revenue accounted for 72.65% of the company’s total revenue in 2021, and its profit accounted for 90.95% of the company’s net profit attributable to the parent company Everbright Securities Company Limited(601788) research indicates that in 2022, the company launched a new strategy, and ikxin was promoted from 0-3 years old to 6 years old. With the company’s past academic promotion and professional category education experience, it is expected that the ceiling of ikxin’s industry will be further opened. It is expected that vitamin D3 is expected to surpass ikxin and become the next billion level single product in the future.
Fu Pengbo’s new position Suzhou Maxwell Technologies Co.Ltd(300751)
With the adjustment of some stocks, Fu Pengbo, manager of Ruiyuan fund, increased the allocation of relevant stocks during the fourth quarter of last year. Previously, the list of top ten shareholders by the end of 2021 disclosed by Shandong Sinocera Functional Material Co.Ltd(300285) , Shanghai Bright Power Semiconductor Co.Ltd(688368) , Hunan Sokan New Materials Co.Ltd(688157) , etc. showed that the Ruiyuan growth value managed by Fu Pengbo had been increased to varying degrees.
On March 11, Suzhou Maxwell Technologies Co.Ltd(300751) disclosed the annual report of 2021. Ruiyuan growth value newly became the top ten shareholders of the company. In the fourth quarter, it newly held 1.1044 million shares, with a market value of 709 million yuan. On February 28, the company disclosed the shareholding of the top ten shareholders of repurchased shares, which showed that Ruiyuan’s growth value continued to increase its position Suzhou Maxwell Technologies Co.Ltd(300751) . From January to February this year, it increased its shareholding by 253000 shares, the number of shares held increased to 1357400 shares, and the market value of its shareholding was 728 million yuan.
The huitianfu value selection managed by Lao jienan, the fund manager of huitianfu, reduced some positions. The company disclosed the shareholding of the top ten shareholders of share repurchase on February 28, which showed that huitianfu value selection directly withdrew from the list of the top ten shareholders.
According to public information, Suzhou Maxwell Technologies Co.Ltd(300751) is a high-end intelligent equipment manufacturer integrating mechanical design, electrical development, software algorithm development and precision manufacturing equipment. It is involved in Cecep Solar Energy Co.Ltd(000591) battery production equipment. It is a world leading equipment supplier and service provider in the photovoltaic industry. The company achieved a revenue of 3.095 billion yuan in 2021, with a year-on-year increase of 35.44%; The net profit attributable to the parent company was 643 million yuan, a year-on-year increase of 62.97%.
Minsheng securities research believes that the core reason for the company to maintain high growth rate of performance is that the photovoltaic industry continues to be booming, and the sales of Cecep Solar Energy Co.Ltd(000591) battery complete equipment of the company’s main business has increased steadily, which makes the net profit of the company maintain a high growth rate in 2021.
In addition, the company continues to lay out in the field of semiconductor and OLED laser cutting, or add new business growth points to the company. Minsheng securities expects the company to achieve revenue of 4.764 billion yuan, 6.218 billion yuan and 9.995 billion yuan from 2022 to 2024, and the net profit attributable to the parent company is 959 million yuan, 1.304 billion yuan and 2.241 billion yuan respectively.
